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Abstract
Ovarian carcinoma (OCa) continues to be the leading cause of death due to gynecologic
malignancies and the vast majority of OCa is derived from the ovarian surface epithelium (OSE)
and its cystic derivatives. Epidemiological evidence strongly suggests that steroid hormones,
primarily estrogens and progesterone, are implicated in ovarian carcinogenesis. However, it has
proved difficult to fully understand their mechanisms of action on the tumorigenic process. New
convincing data have indicated that estrogens favor neoplastic transformation of the OSE while
progesterone offers protection against OCa development. Specifically, estrogens, particularly those
present in ovulatory follicles, are both genotoxic and mitogenic to OSE cells. In contrast,
pregnancy-equivalent levels progesterone are highly effective as apoptosis inducers for OSE and
OCa cells. In this regard, high-dose progestin may exert an exfoliation effect and rid an aged OSE
of pre-malignant cells. A limited number of clinical studies has demonstrated efficacies of
antiestrogens, aromatase inhibitors, and progestins alone or in combination with chemotherapeutic
drugs in the treatment of OCa. As a result of increased life expectancy in most countries, the
number of women taking hormone replacement therapies (HRT) continues to grow. Thus,
knowledge of the mechanism of action of steroid hormones on the OSE and OCa is of paramount
significance to HRT risk assessment and to the development of novel therapies for the prevention
and treatment of OCa.
Introduction
Ovarian carcinoma (OCa) continues to be the leading
cause of death due to gynecologic malignancies. Over
23,300 will be diagnosed and 13,900 patients will die in
2003 from OCa [1]. The incidence of OCa varies widely in
frequency among different geographic regions and ethnic
groups, with high incidences observed in Scandinavia,
Western Europe and North America and low incidences
found in Asian countries [2]. The majority of cases is spo-
radic while about 5% to 10% of OCa is familial. Although
all cell types of the human ovary may undergo neoplastic
transformation, the vast majority (80–90%) of benign
and malignant tumors are derived from the ovarian sur-
face epithelium (OSE) and its cystic derivatives [3,4]. The
origin of OSE could be traced to the mesothelium of the
embryonic gonads, or the Mullerian epithelium, and
therefore OCas often resemble those of the fallopian tube,
endometrium, and endocervix [4,5].
Incessant ovulation is a probable cause of 
ovarian carcinogenesis
A long-standing hypothesis has been proposed to explain
the causal mechanism of ovarian carcinogenesis. The
"incessant ovulation" hypothesis argues that repeated
cycles of ovulation-induced trauma and repair of the OSE
at the site of ovulation, without pregnancy-induced rest
periods, contributes to ovarian cancer development [6,7].
According to this hypothesis, successive bouts of apopto-
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sis and regenerative repair of OSE cells at the ovulation
site induces genetic instability, which predisposes this cell
layer to tumorigenesis. Studies in the ewe provided exper-
imental evidence in support of this theory. Oxidative
DNA damage, expression of p53, and apoptosis occur
among the OSE cells within the formative site of ovula-
tion [8]. Concomitantly, the anti-apoptotic Bcl-2 and the
base excision repair enzyme polymerase-beta are overex-
pressed in OSE cells at the margins of ruptured follicles.
Following exfoliation of OSE cells at the dome of the ovu-
latory follicles, repair is accomplished by replication of
cells at the margin and their migration to the wound [9].
Survival and subsequent clonal expansion of OSE cells
with unrepaired genomic damage and heightened sur-
vival potential may present itself as a risk factor for ovar-
ian carcinogenesis. Therefore, with each cycle of ovulation
an increased number of genetically altered cells accumu-
lates in the OSE and raises the risk of tumor initiation. In
agreement with findings in the sheep, a recent study
reported that tumorigenecity in human OCa cells col-
lected from effusions was associated with abnormal
expression of p53, which plays a key role in regulating
DNA damage-induced apoptosis [10].
Hormone replacement therapy (HRT) and 
ovarian cancer risk
As life expectancy increases in most countries, progres-
sively more women are expected to spend over one third
of their life post-menopausally. To ameliorate symptoms
of the climacteric, primarily vasomotor flashes and
sweats, estrogen-based hormone replacement therapy
(HRT) is used by millions of women around the world.
For some, longer-term usage (> 5 years) is often necessary
to relieve persistent symptoms. Others continue to use the
therapy for prevention of a number of aging-related dis-
eases including osteroporosis, myocardial infarction,
strokes, dementia, and possibly Alzheimer's disease. Justi-
fications for longer-term usage are in part based on find-
ings from observational studies that suggest a protective
effect of estrogen against bone loss, atherosclerosis and
memory deficit [11]. However, recently published results
from a randomized trial, the Women's Health Initiative
(WHI), indicate significant increases in the incidences of
breast cancer, thromboembolic diseases, and dementia in
women using the HRT with combined estrogen and pro-
gestin [12,13]. These results have led to the early termina-
tion of this arm of the trial and raised great concerns
among women and the medical community regarding the
safety of HRT usage. The premature termination of the
estrogen plus progestin arm makes it difficult to interpret
and compare results from other arms of the WHI trial and
has significantly undermined future trials that aim at test-
ing the impacts of other post-menopausal therapies on
disease development, including OCa.
Observational data suggest there may be a small increased
risk of OCa associated with longer-term use of HRT [14–
16]. However, the evidence from these studies is in disa-
greement with other reports that detected an unchanged
[17,18] or a reduced [19,7,20] risk of developing the can-
cer. Intriguingly, the Heart and Estrogen/progestin
Replacement Study (HERS) II trial, a randomized trial of
post-menopausal hormones, has recently reported no dif-
ference in OCa incidence between the HRT and the pla-
cebo group [21]. Since placebo controlled, randomized
clinical trials are usually considered to be "gold stand-
ards" to assess the real risks and benefits of chronic treat-
ments, results from the HERS II might ease concerns
regarding HRT and OCa risk among some users. Explana-
tions for the discrepancies among various studies and
those between observational studies and clinical trials
have been attributed to differences in methodologies and
existence of uncontrolled confounding factors. To date,
questions pertaining to the effects of estrogens and/or
progestins on ovarian carcinogenesis remain unanswered.
Estrogens are implicated as causative factors of 
ovarian carcinogenesis
Estrogens have long been suspected as etiologic factors of
OCa. Although usage of estrogen-based oral contracep-
tives is known to reduce OCa risk, its effect is primarily
attributed to reduction in ovulation frequency. Ovarian
tissue estrogen levels are at least 100-fold higher than cir-
culating levels and those in the follicular fluid of ovula-
tory follicles are even higher [22]. Thus, OSE and its cystic
derivatives are likely to be exposed to high levels of these
steroids. Literature from breast cancer research has dem-
onstrated direct genotoxic effects of estrogen [23]. Hence,
it is logical to speculate that genomic damage of OSE cells,
covering the ovulating follicles or in inclusion cysts may,
in part, be caused by the high levels of estrogen in the fol-
licular fluid or in the ovarian stroma.
In addition to inducing genetic damages to OSE cells,
Syed et al [24] have reported estrogen receptor (ER)-medi-
ated growth stimulatory responses of normal and malig-
nant OSE cells to estradiol-17 beta and estrone. Worthy of
mentioning is the observation that estradiol-17 beta and
estrone are of equal potency in stimulating growth in OSE
cells although it is well known that estrone is a much less
potent estrogen when compared to estradiol-17beta. This
is an important finding because, after menopause, estrone
is the major circulating estrogen produced as a result of
aromatization from androstenedione in skin and adipose
tissue [25]. In this regard, a recent prospective study on
postmenopausal women found higher OCa mortality
rates among overweight [Body Mass Index (BMI) >/ = 25]
and obese (BMI >30) women [26] suggesting that periph-
eral estrogen formation is probably a promotional factor
for OCa progression. Furthermore, it was demonstrated
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that the mitogenic effects of estrogens, and those of
androgens and gonadotropins, on OSE cells were medi-
ated through activation of the IL-6/STAT-3 signaling path-
way and that OCa cells expressed high levels of
constitutively activated STAT-3, a known transforming
cellular molecule [27]. Lastly, a recent study examined pri-
mary cell cultures derived from twenty-five OCa patients
and found that tumor cells secreted estradiol-17 beta, but
not testosterone nor progesterone. In this study, the estro-
gen was shown to exert antiapoptotic effects on OCa cells.
The ability of OCa cells to produce estradiol-17 beta
implicates an auto-/paracrine-influence of this steroid on
OCa progression.
Taken together, it is reasonable to speculate that the com-
bined genotoxic and mitogenic effects of estrogens consti-
tute a potent force for the neoplastic transformation of
normal OSE cells. In addition, circulating and/or in situ
produced estrogens, via growth stimulation and inhibi-
tion of apoptosis, likely play critical roles in tumor initia-
tion and promotion [28,24].
Progesterone is implicated as a protective factor 
against OCa
Progesterone (P4) or cellular responses to P4 appears to
offer protection against ovarian carcinogenesis. Of signif-
icance, loss of heterozygosity at 11q23.3-24.3 that har-
bors the progesterone receptor (PR) gene locus is
commonly observed in OCa specimens [≈75%, [29–31]]
and this genetic alteration is associated with poor progno-
sis [31]. These findings thus implicate PR as a tumor sup-
pressor gene. Epidemiological data provide additional
support that P4 or response of OSE cells to the steroid
affords a protective role against OCa development or pro-
gression. An increase in ovarian cancer incidence was
observed among women with progesterone deficiency
[32]. In contrast, increased parity is associated with a
reduction in OCa risk [33,34]. The protective effect of
pregnancy may be attributable to exposure of the OSE to
high levels of P4 during pregnancy [35]. In concordance,
women with a history of twin pregnancies exhibit a lower
risk for developing OCa, possibly due to higher levels of
P4 found in maternal circulation during twin pregnancies
when compared to singleton pregnancies [36,33]. Intrigu-
ingly, unlike breast cancer, a pregnancy at advanced age is
more protective than one at young age against OCa [34].
This later observation supports the "exfoliate" theory of
OCa protection. It theorizes that pregnancy levels of P4
rid the OSE of genetically damaged, pre-malignant cells
and hence reduce the risk of tumorigenesis during subse-
quent years.
Expression of progesterone and estrogen 
receptors in OSE and OCa
Until recently, little was known about expression levels of
the estrogen receptors (ERs) and PRs in ovarian tumors or
in normal OSE. Using semiquantitative RT-PCR, Lau and
co-workers [37] demonstrated expression of ER-alpha and
ER-beta mRNA, as well PR mRNA, in primary cultures of
normal OSE cells. A moderate reduction in ER-alpha
mRNA expression, accompanied by a marked downregu-
lation of PR expression, was noted in OCa cell lines when
compared OSE cells. Lee et al [38] reported 86% of ovar-
ian tumor specimens stained positive for ER, 50% positive
for PR, and 45% positive for both receptors. In another
study, PR immunopositivity was observed in the majority
of borderline tumors, whereas almost all (93%) malig-
nant ovarian tumors stained negative for PR [39]. Among
the various OCa subtypes, ER-alpha immunostaining was
found in 97% of serous adenocarcinomas, 100% of
endometrioid adenocarcinomas, 70% of mucinous aden-
ocarcinomas and none of the clear cell carcinoma speci-
mens (0%) [40]. In contrast, ER-beta immunopositivity
was found in all OCa subtypes (39% of clear cell carci-
noma, 41% of serous adenocarcinoma, 30% of mucinous
adenocarcinomas, and 75% of endometrioid adenocarci-
noma). Except for clear cell carcinomas, PR was expressed
in 30% to 70% of the various OCa subtypes in this study.
Another investigation had compared expression levels of
the two major PR isoforms, PR-A and PR-B, in ovarian
tumors and in normal and benign ovarian tissues [41]. No
significant difference was noted in the expression levels of
PR-B among normal/benign ovarian tissues and cancer-
ous specimens. In contrast, PR-A was found to be
expressed in normal and benign ovarian tissues but exhib-
ited marked reduction in malignant cancer specimens. In
ovarian cancer cell lines (OVCAR-3 and Caov-3), the PR-
B/PR-AB mRNA ratio was elevated by estradiol-17 beta in
both a time- and dose-dependent manner [41]. However,
this ratio was unaltered when a normal OSE cell line
(NOV-31) was exposed to the steroid. At the protein level,
treatment with estradiol-17 beta markedly upregulated
PR-B expression in OVCAR-3 while both PR-A and PR-B
isoforms were elevated in NOV-31 by the hormone treat-
ment. All in all, it appears that the two PR subtypes are dif-
ferentially regulated by estrogen and differentially
expressed between normal OSE and OCa. A loss of PR-A
was found to be associated with ovarian malignancy. The
cause for the loss of PR expression is unknown but may be
related to a diminution in estrogen responsiveness in OCa
cells [40] and/or a second 'hit' following loss of PR heter-
ozygosity [29–31]. In this regard, somatic mutations in
the primary sequences of PRs have not been reported in
OCa. Since a recent study has demonstrated DNA hyper-
methylation-mediated silencing of PR-B in human uterine
endometrial cancer [42] this mechanism of transcrip-
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tional inactivation of PRs in OCa needs to be investigated
in future studies.
PROGINS refers to a group of complex PR gene polymor-
phisms [43,44]. It includes a polymorphism in intron G
of the human PR, caused by an Alu insertion, a G to T sub-
stitution in exon 4, causing a Valine to Leucine change in
the hinge region of the receptor, and a synonymous C to
T substitution in exon 5 reported to be linked to the Alu
insertion. It was demonstrated that the PROGINS allele
codes for a PR with increased stability and increased hor-
mone-induced transcriptional activity. PROGINS poly-
morphism was reported to be associated with OCa in a
number European and North American Caucasian popu-
lations [43,45,46] and the PROGINS allele has been spec-
ulated as a modifying gene in hereditary OCa. However, a
recent study in an Australian population found no associ-
ation between PROGINS and increased risk for OCa [44].
Additionally, the protein levels of ER and PR in OCa spec-
imens were independent of the PROGINS status [44].
Some studies did not find a strong correlation between
OCa progression and PR and/or ER gene expression
[47,41]. However, one recent report has demonstrated
that PR-B labeling index (immunopositivity) is an inde-
pendent prognostic factor for OCa [48]. In addition, it
was shown that the ER-negative and PR-positive (ER-PR+)
OCas, which accounted for approximately 10% of all
tumors, showed a significantly superior prognosis when
compared with all other combinations of ER and PR
expression statuses [49]. Five-year survival rate was over
80% for ER-PR+ tumors versus 45% for tumors expressing
all other steroid hormone receptor combinations. Finally,
it has been speculated that the loss of ER expression in
OCa may explain the disappointing responses of OCa
patients to antiestrogen therapy such as tamoxifen [50].
Mechanism of P4-mediated anti-OCa action
A handful of in vitro studies have demonstrated an inhib-
itory action of P4 on OCa cell growth [51–54,27]. Others
showed a clear induction of apoptosis in OCa cells by the
steroid [51–54]. Alterations in apoptosis regulators such
as bcl-2, c-myc and p53 were detected in OCa cells under-
going apoptosis [52,30]. Relatively high doses of P4 (1
µM range) were used in these studies to achieve growth
inhibition and apoptosis. In a recent investigation, the
effects of P4 on normal OSE and OCa cells were studied
simultaneously across a 6-log concentration range (10-11
to 10-6 M). Results from this study demonstrated a growth
promoting effect of P4 at low concentrations (below 10-8
M) and a growth inhibitory action of P4 at higher concen-
trations [24]. These observations are consistent with the
belief that regenerative proliferation of the OSE after ovu-
lation involves P4. Furthermore, P4 may promote repair
of ovulation-induced genomic damages during early
luteal phase via induction of polymerase-beta activity as
suggested by experiments in OSE cells derived from the
ewe [9]. In contrast, higher doses of P4, in the range expe-
rienced during pregnancy or perhaps during oral contra-
ceptive usage, induce cell cycle arrest or apoptosis in
normal OSE cells and OCa cells. Of significance, Syed and
Ho [55] recently demonstrated that the P4-induced apop-
tosis in both normal OSE and OCa cell cultures utilized
an extrinsic apoptosis-initiation pathway involving activa-
tion of caspase-8 rather than the intrinsic, mitochon-
drion-related caspase-9 pathway. They further showed
that the P4-induced caspase-8 activation led to an
enhancement of Fas/FasL signalling which might ulti-
mately be responsible for apoptosis induction in OSE and
OCa cells. In concordance, an earlier study found that the
cytotoxic effect of an anti-Fas antibody on an OCa cell line
(NOS4) was dependent on the activation of caspase-8
[56]. Among the TNF receptor family, Fas (APO-1/CD95),
is recognized as an important death receptor that serves to
transmit extracellular apoptotic signals intracellularly
[57,58]. Activation of the receptor is normally accom-
plished by binding of the Fas ligand (FasL) but could also
be achieved by interaction with an anti-Fas antibody
[59,60]. The Fas/FasL system was first known to play an
important role in eliminating self-damaging T cells. More
recently, this signalling system has been shown to be a
prime mediator of therapeutic cell kill in a variety of can-
cer cells, including those derived from the OSE [61]. In
conclusion, these studies now establish a connection
between P4 action and Fas/Fas L signaling in normal and
malignant OSE cell death.
Another mechanism by which P4 exerts its antitumori-
genic action is via reduction of fluid dynamics of plasma
membranes in OCa cells [62]. The decrease in membrane
fluidity has been demonstrated to be related to in vitro
inhibition of exocytotic vesicle release, cell invasiveness in
Matrigel, and colony formation in collagen matrix.
Importantly, inhibition of in vivo tumorigenesis in immu-
nocompromised nude mice has also been demonstrated
in this study.
Lastly, new evidence has emerged that indicates the anti-
tumorigenic effects of P4 may be mediated by induction
of alternative expression of transforming growth factor-
beta (TGF-beta) isoforms in OSE. When ovaries from the
control and estrogen-only-treated monkeys were com-
pared to the ovaries of progestin-treated monkeys a
marked decrease in the expression of TGF-beta1 and a
concomitant increase in the expression of the TGF-beta2/
3 isoforms was observed in the OSE. The P4 induced
switch from TGF-beta1 to TGF-beta 2/3 expression was
highly correlative to increased apoptotic index in the OSE.
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Clinical use of antiestrogens in the treatment of 
OCa
Initial clinical studies demonstrated that the use of
tamoxifen, a first generation antiestrogen, for relapsed
OCa treatment was far from effective [63,64]. In one
study, when 105 patients with Stage III or IV epithelial
OCa with recurred disease were treated with tamoxifen
10% demonstrated a complete response, 8% showed a
partial response, and 38% had short-term disease stabili-
zation [63]. The response or stabilization period was
between 7 to 19 months and patients with high levels of
ER appeared to respond better. Another study has used the
antiestrogen in cisplatin-refractory OCa patients and
demonstrated a modest objective response rate of 13%
[65]. Therefore, the use of tamoxifen alone for treatment
of OCa has made little advancement since these earlier tri-
als. Recently, it has been shown that tamoxifen may be
able to synergize standard platinum-based OCa treatment
[66]. Fifty patients with recurrent OCa received platinum-
based chemotherapy (cisplatin or carboplatin) before
they were treated with tamoxifen. This combined treat-
ment regimen was found to produce an overall response
rate of 50% (complete response 30%; partial response
20%) with a median duration of 8.5 months (3–42
months). These results have raised optimism that an anti-
estrogen could be used in combination with platinum-
based therapies to provide more effective treatments for
OCa. Furthermore, with the new knowledge that OCa
cells may produce their own estrogens [25] the use of an
aromatase inhibitor may further enhance the response. In
a small clinical study, 50 patients were treated with the
aromatase inhibitor letrozole and evaluated by UICC cri-
teria [67]. Although no complete or partial responses were
obtained, 10 patients had stable disease on scan for at
least 12 weeks. Letrozole treatment also induced higher
levels of ER expression in the tumors, a condition believed
to favor a response to antiestrogen. Findings from these
trials suggest that treatment of patients with letrozole
alone or in combination with other therapeutic regimens
may result in longer-term survival in subgroups of
patients.
Clinical use of progestins as chemopreventive 
and treatment agents against OCa
Several pre-clinical studies have tested the efficacy of P4 to
prevent OCas. Using the laying hen, Gallus domesticus, as a
model of spontaneous ovarian carcinogenesis, it was
found that medroxyprogesterone acetate (MPA or Depo-
Provera) reduced the frequency of spontaneously devel-
oping reproductive tract adenocarcinoma including OCa
in the avian model [68]. The mechanism of action of P4 is
believed to be directly related to a reduction of ovulatory
events in this avian species. Similarly, it has been demon-
strated that monkeys treated with the progestin-compo-
nent of the oral contraceptive (levonorgestrel) have
increased apoptosis in the ovarian epithelium cells as
compared with controls and ethinyl estradiol-treated
monkeys [69]. Thus results from the latter study suggest
that the anti-OCa effects of P4 may be beyond inhibition
of ovulation but more directly related to its pro-apoptotic
action on OSE cells. As discussed above, removal of OSE
cells reduces the number of cells with pre-malignant
lesions in this tissue, which has the propensity to accumu-
late genetically damaged cells through repeated ovula-
tions.
Injectable progestins have been widely used as contracep-
tives by women of the third world under the USAID pro-
gram [70]. Depot medroxyprogesterone acetate (MPA),
marketed under the brand name Depo-Provera, taken
every 3 months, is by far the most commonly used [71].
Another progestin-only injectable is norethindrone enan-
thate (NET EN), taken every 2 months. It is estimated that
more than 30 million women in 90 countries have used
injectable progestins to prevent conception with a current
usage rate of 9 million, most popular among women in
Thailand and Indonesia. In 1992, the US Food and Drug
Administration (FDA) approved the use of Depo-Provera
as a contraceptive in the United States. Furthermore,
Depo-Provera has been approved for non-contraceptives
usage such as treatment of endometrial cancer since 1969.
However, progestins have not been considered as a chem-
opreventive agent for high risk populations primarily due
to concerns of a possible link between long term progestin
usage and risks of breast and cervical cancers [14,72].
Recent research, however, demonstrated no connection
between Depo-Provera usage and cervical and ovarian
cancer risk. The progestin was further shown to reduce
endometrial cancer incidence [70]. Moreover, a recent
observational study found that survival in 33 patients
with poorly differentiated OCas correlated with higher
serum progesterone, especially in combination with
expression of PR [73].
The major unease that prevents considering using pro-
gestins as chemopreventive agents for OCa resides in the
possibility of increased breast cancer risk. Based on the
weight of current experimental and observational study
evidence a rationale approach would be to treat high risk
women with pregnancy equivalent level of progestin for a
short duration in order to induce the "exfoliation" effect
of P4 on the OSE. Future clinical trials are needed to deter-
mine the efficacy of high dose progestin treatment in OCa
prevention.
An earlier randomized trial demonstrated that MPA or
MPA plus tamoxifen were not effective in causing OCa
regression. However, both treatments stabilized the can-
cer for 4 to 16 months [74]. Data from a small clinical
study on stage III recurrent OCa patients suggested that
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progesterone combined with platinum-based chemother-
apy as a first-line therapy may improve the prognosis of
advanced epithelial ovarian cancer, but had little effects
on the prognosis of early stage epithelial OCa [75].
Conclusion
Despite recent gains in our knowledge of regulation of cell
proliferation and apoptosis in normal OSE and in OCa by
estrogens and progesterone, the relationships between
these steroids and ovarian carcinogenesis remain poorly
understood. The weight of evidence suggests that estro-
gens, particularly those present in the intra-follicular fluid
of ovulatory follicles, may contribute to initiation and/or
promotion of ovarian carcinogenesis, whereas progester-
one, at levels equivalent to those found during pregnancy,
may offer protection against OCa development. The cur-
rent knowledge base also reveals significant differences
exist in the responses of various female tissues to estrogen
and progesterone, or their combined action. Although the
molecular bases of these differences are not fully under-
stood it is safe to speculate that they are mediated, in part,
by the different levels of ER and PR subtypes expressed in
these tissues. Additionally, expression levels of the various
steroid receptor co-regulators must also play an important
role in modulating tissue sensitivity and responsiveness.
From a clinical perspective, a more in-depth understand-
ing of the action of estrogens and progestins on normal
and malignant OSE cells is of paramount significance to
HRT risk assessment. Furthermore, if issues revolving
around the adverse effects of progestins on mammary car-
cinogenesis could be resolved, the use of progestins for
OCa prevention in high risk populations would become
an attractive option. As selective estrogen receptor modu-
lators have been developed to circumvent the uterine can-
cer risk of estrogen-based HRT, selective progesterone
receptor modulators could be produced in the future to
offer protection against OCa while sparing the mammary
gland of a tumor promoting action. Finally, the combined
use of progestins with various chemotherapeutic agents
continues to hold promise for new treatment regimens to
be developed for OCa.
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